Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
Talking Rheumatology Research - Ep 47. Relapse after cessation of weekly tocilizumab for giant cell arteritis

Ep 47. Relapse after cessation of weekly tocilizumab for giant cell arteritis

08/25/24 • 11 min

Talking Rheumatology Research

Dr. Vanessa Quick joins Dr. Ernest Choy to discuss her recent article on the impact of qwTCZ cessation on GCA patients.

Looking at relapse rates and key risk factors, this discussion highlights the need for improving access to care and treatment for GCA patients, including increasing disease awareness, faster referral to specialised care, better access to diagnostic tools, and a multidisciplinary approach to managing this condition.

You can read this article [https://doi.org/10.1093/rheumatology/kead604] in Rheumatology.

The countdown to #BSR25 begins!
Our full Annual Conference 2025 programme is now available. Browse 100+ sessions and get ready for an inspiring event.
https://bit.ly/4bGFX1N

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

plus icon
bookmark

Dr. Vanessa Quick joins Dr. Ernest Choy to discuss her recent article on the impact of qwTCZ cessation on GCA patients.

Looking at relapse rates and key risk factors, this discussion highlights the need for improving access to care and treatment for GCA patients, including increasing disease awareness, faster referral to specialised care, better access to diagnostic tools, and a multidisciplinary approach to managing this condition.

You can read this article [https://doi.org/10.1093/rheumatology/kead604] in Rheumatology.

The countdown to #BSR25 begins!
Our full Annual Conference 2025 programme is now available. Browse 100+ sessions and get ready for an inspiring event.
https://bit.ly/4bGFX1N

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Previous Episode

undefined - Ep 46. Patient involvement in Rheumatology research

Ep 46. Patient involvement in Rheumatology research

Peter Boyd and Ingrid de Groot join Dr. Latika Gupta to explore the value of patient involvement in Rheumatology research. Reflecting on their lived experience, Peter and Ingrid discuss their proudest moments, and identify areas in the patient and physician partnership that they hope to improve in the future.

The countdown to #BSR25 begins!
Our full Annual Conference 2025 programme is now available. Browse 100+ sessions and get ready for an inspiring event.
https://bit.ly/4bGFX1N

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Next Episode

undefined - Ep 48. Deciphering difficult-to-treat psoriatic arthritis

Ep 48. Deciphering difficult-to-treat psoriatic arthritis

Should there be distinct definitions for difficult-to-treat and complex-to-manage psoriatic arthritis?

In this episode of Talking Rheumatology Research, Dr Fabian Proft and Dr Andre Ribeiro join Dr Ai Lyn Tan to discuss their work to define difficult-to-treat psoriatic arthritis, as part of GRAPPA's wider D2T-PsA project.

Find out more:

  1. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals
  2. Find out more about GRAPPA and its work

Keywords: psoriatic arthritis, PSA, difficult-to-treat, D2T, complex-to-manage, C2M, GRAPPA, rheumatology.

The countdown to #BSR25 begins!
Our full Annual Conference 2025 programme is now available. Browse 100+ sessions and get ready for an inspiring event.
https://bit.ly/4bGFX1N

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/talking-rheumatology-research-280592/ep-47-relapse-after-cessation-of-weekly-tocilizumab-for-giant-cell-art-72171425"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to ep 47. relapse after cessation of weekly tocilizumab for giant cell arteritis on goodpods" style="width: 225px" /> </a>

Copy